← All Quoin Pharmaceuticals, LTD filings

Quoin Pharmaceuticals, LTD DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
QNRX
Quoin Pharmaceuticals, LTD
DEF: Quoin Pharmaceuticals Annual Meeting Proxy Statement
Quoin Pharmaceuticals Ltd. is holding its 2026 Annual General Meeting on August 20, 2026, to vote on director elections, executive compensation, director compensation program changes, 401(k) plan adjustments, and auditor appointment.
NASDAQ
QNRX
Quoin Pharmaceuticals, LTD
DEF: Quoin Pharmaceuticals Seeks Shareholder Approval for Massive Capital Increase and New Equity Plan Amidst Continued Losses
Quoin Pharmaceuticals Ltd. has called its 2025 Annual General Meeting to approve a significant increase in authorized share capital, a new executive compensation policy, and a new equity incentive plan, following a period of consistent net losses and a substantial decline in shareholder value.
NASDAQ
QNRX
Quoin Pharmaceuticals, LTD
DEF 14A: Quoin Pharmaceuticals Seeks Shareholder Approval for Director Elections, Compensation Programs, and Charter Amendments at Upcoming Annual Meeting
Quoin Pharmaceuticals is holding its Annual General Meeting on December 5, 2024, to vote on director elections, executive compensation, amendments to the Articles of Association, and appointment of an independent auditor.
NASDAQ
QNRX
Quoin Pharmaceuticals, LTD
DEFA14A: Quoin Pharmaceuticals Ltd. Adjourns Special General Meeting Due to Lack of Quorum
Quoin Pharmaceuticals Ltd. adjourned its Special General Meeting on March 29, 2024, due to a lack of quorum and will reconvene on April 5, 2024.
NASDAQ
QNRX
Quoin Pharmaceuticals, LTD
DEF 14A: Quoin Pharmaceuticals Seeks Shareholder Approval for $8 Million Alumni Capital Equity Line
Quoin Pharmaceuticals is asking shareholders to approve the issuance of shares related to an $8 million purchase agreement with Alumni Capital LP at a special general meeting on March 29, 2024.